Skip to content

ANAVEX LIFE SCIENCES CORP.: 10-Q filed 2023-02-07

What ANAVEX LIFE SCIENCES CORP. reported in its quarterly report filed 2023-02-07 (fiscal Q1 2023): 23 published measures, 49 facts as tagged in accession 0001731122-23-000152.

This filing

Form
10-Q (quarterly report)
Filed
2023-02-07
Fiscal period
fiscal Q1 2023
Accession
0001731122-23-000152 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANAVEX LIFE SCIENCES CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-12-31148,371,922USD
At 2022-09-30152,704,603USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-12-3113,247,846USD
At 2022-09-3010,213,561USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-12-31135,124,076USD
At 2022-09-30142,491,042USD
At 2021-12-31146,367,706USD
At 2021-09-30150,818,104USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-12-31143,621,848USD
At 2022-09-30149,157,861USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-10-01 to 2022-12-31-12,971,718USD92
2021-10-01 to 2021-12-31-10,882,367USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-10-01 to 2022-12-31-5,794,257USD92
2021-10-01 to 2021-12-31-3,500,955USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-10-01 to 2022-12-31258,244USD92
2021-10-01 to 2021-12-312,539,565USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-12-31-258,535,501USD
At 2022-09-30-245,563,783USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-10-01 to 2022-12-315,346,508USD92
2021-10-01 to 2021-12-313,908,771USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-10-01 to 2022-12-31-15,383,955USD92
2021-10-01 to 2021-12-31-11,723,390USD92

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-12-315,288,261USD
At 2022-09-303,824,777USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-10-01 to 2022-12-3115,383,955USD92
2021-10-01 to 2021-12-3111,723,390USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-10-01 to 2022-12-3112,066,919USD92
2021-10-01 to 2021-12-318,656,439USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-12-3178,032,135shares
At 2022-09-3077,942,815shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2022-12-31143,621,848USD
At 2022-09-30149,157,861USD
At 2021-12-31151,146,355USD
At 2021-09-30152,107,745USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2022-12-317,042,822USD
At 2022-09-305,944,953USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2022-12-31655,643USD
At 2022-09-30354,162USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2022-10-01 to 2022-12-31-12,991,764USD92
2021-10-01 to 2021-12-31-10,852,387USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-10-01 to 2022-12-313,317,036USD92
2021-10-01 to 2021-12-313,066,951USD92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-10-01 to 2022-12-312,392,191USD92
2021-10-01 to 2021-12-31871,003USD92

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2022-10-01 to 2022-12-31-20,046USD92
2021-10-01 to 2021-12-3129,980USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-10-01 to 2021-12-312,312,785USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-10-01 to 2022-12-311,463,484USD92
2021-10-01 to 2021-12-31-104,992USD92

Inspect the source

Entity
ANAVEX LIFE SCIENCES CORP. / CIK 0001314052
Captured
2026-09-20T07:51:32.244Z
SEC response SHA-256
58235b1aa01b2e3fa186f80cce94f8ff6bd171b1d8823aeeecb0ffde54d83b04

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001314052.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))